SecBot SecBot
DEFA14A ·Filed Mar 23, 2026

HALO

HALOZYME THERAPEUTICS, INC.
NEUTRAL
Impact 2/10
Horizonweeks Processed7mo ago SEC0001159036-26-000042
Proxy solicitation materials
Actionable Insight • Neutral

Monitor for the full proxy statement which may contain details about director elections, executive compensation, or shareholder proposals

DirectionNeutral
Confidencelow
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$62.04
T+0 close · Mar 23, 2026 · via day close
Latest settled
+10.49%
T+60 · $68.55
Vs SPY
−3.83%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 24 $62.04entry
  2. T+1 · 8mo ago +1.93%α +1.37% · $63.24
  3. T+5 · 8mo ago +4.17%α +4.60% · $64.63
  4. T+20 · 7mo ago +10.25%α +1.35% · $68.40
  5. T+60 · 5mo ago +10.49%α −3.83% · $68.55
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Analysis based on filing metadata only, document content was unavailable

Key Facts

  • Filing is a DEFA14A (Definitive Additional Materials) for a proxy statement
  • Filed by Halozyme Therapeutics, Inc. (HALO)
  • No financial data or specific event details available in provided documents

Financial Impact

No financial impact data available

Risk Factors

  • Lack of complete information prevents assessment of potential market impact
  • Proxy statements may contain important governance information that could affect investor sentiment

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001159036-26-000042
Document: 0001159036-26-000042-index-headers.html0001159036-26-000042
Document: 0001159036-26-000042-index.html0001159036-26-000042
Document: 0001159036-26-000042.txt0001159036-26-000042

Track record

15 reports on HALO

Performance horizon

1 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +17.70% at T+20 after the Oct 15, 2026 report. 4 of 6 went positive at some point.

Filters
  1. Nov 9, 20268d ago PTAB Trial Bearish 6/10 Entry $102.98 Now $96.50 +6.29% settles Nov 17
  2. Nov 6, 202610d ago Press Release Bullish 6/10 Entry $103.63 to $100.27 Now $96.50 −6.88% ▼ −3.24% −5.84% vs SPY
  3. Nov 5, 202611d ago 8-K Bullish 6/10 Entry $103.63 to $100.27 Now $96.50 −6.88% ▼ −3.24% −5.84% vs SPY
  4. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $124.54 to $131.18 Now $96.50 −22.51% ▲ +5.33% +4.62% vs SPY
  5. Oct 20, 202627d ago Institutional Cluster Bullish 4/10 Entry $124.83 to $128.50 Now $96.50 −22.69% ▲ +2.94% +3.38% vs SPY
  6. Oct 15, 20264w ago PTAB Trial Bearish 7/10 Entry $121.84 to $125.63 Now $96.50 +20.80% ▼ −3.11% −3.54% vs SPY
  7. Oct 15, 20264w ago PTAB Trial Bearish 7/10 Entry $121.84 to $125.63 Now $96.50 +20.80% ▼ −3.11% −3.54% vs SPY
  8. Sep 18, 20268w ago 8-K Mixed 6/10 Entry $112.45 to $113.90 Now $96.50 −14.18% ▲ +1.29% +0.02% vs SPY
  9. Sep 17, 20268w ago Insider Cluster Neutral 2/10 Entry $112.45 to $113.90 Now $96.50 −14.18% ▲ +1.29% +0.02% vs SPY
  10. Aug 19, 202612w ago Insider Cluster Neutral 2/10 Entry $106.12 to $106.92 Now $96.50 −9.07% ▲ +0.75% −0.36% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 7h 9m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 23, 2026